Market Overview

UPDATE: UBS Securities Upgrades Allergan On Conference Call Takeaways

Share:
Related AGN
Teva Still A 'Must-Own' Stock, Worth $86
Benzinga's M&A Chatter for Monday July 27, 2015
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary (Zacks)

In a report published Tuesday, UBS Securities analyst Marc Goodman upgraded the rating on Allergan (NYSE: AGN) from Neutral to Buy, and raised the price target from $180.00 to $200.00.

In the report, UBS Securities noted, “Investors have been waiting for 2 Allergan events: a restructuring and an accretive deal. Given the Friday PR for the conf call today, many investors were expecting a deal to be announced today and thus were disappointed from that perspective. But the cost cutting was solid and viewed positively (on top of the very strong qtr), and mgt couldn't have been more confident that it can get a deal done in time. Now we wait for this deal. Can Allergan create close to as much ST value as Valeant can with its cost cuts?”

Allergan closed on Monday at $171.14.

Latest Ratings for AGN

DateFirmActionFromTo
Jul 2015BarclaysMaintains
Jul 2015RBC CapitalDowngradesTop PickOutperform
Jun 2015BMO CapitalMaintainsOutperform

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Marc Goodman UBS SecuritiesAnalyst Color Upgrades Analyst Ratings

 

Related Articles (AGN)

Get Benzinga's Newsletters